


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

LFN

APPLICANTS: Simpson et al. GROUP ART UNIT: 3763  
SERIAL NO.: 10/748,589 EXAMINER: Unknown  
FILING DATE: December 30, 2003 ATTY. DOCKET NO.: EIS-5909H (1417G P 984)  
For: MEDICAL DATA COMMUNICATIONS NOTIFICATION AND MESSAGING SYSTEM AND METHOD



Mail Stop: Amendment  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Dear Sir/Madam:

Submitted herewith is an Information Disclosure Statement for consideration in the above-identified application. This Information Disclosure Statement is submitted:

- ☒ Within 3 months (1) of filing date of a national application; (2) of date of entry of the national stage as set forth in 37 CFR §1.491 in an international application; or (3) before the mailing date of a first Office Action on the merits, whichever occurs last. (No fee is required.)
- ☐ After the mailing date of a first Office Action but before (1) mailing of a final action under 37 CFR §1.311, whichever occurs first.
- ☐ Please charge payment for the fee set forth in 37 CFR §1.17(i)(1) to Deposit Account No. 02-1440.
- ☐ The certification specified in 37 CFR §1.97(e) is made below. (No fee is required.)
- ☐ After the mailing of (1) a final action under 37 CFR §1.113; or (2) a notice of allowance under 37 CFR §1.311 whichever occurs first, but before payment of the issue fee. The certification specified in 37 CFR §1.97(e) is made below. The Commissioner hereby is petitioned to consider the Information Disclosure Statement accompanying the submission.
- ☒ The undersigned counsel for applicant(s) hereby certifies that the item of information identified in the Information Disclosure Statement was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement while all others were already cited in previous Information Disclosure Statements and accompanying documents.
- ☐ The undersigned counsel for applicant(s) hereby certifies that some items of information contained in the Information Disclosure Statement were not cited in a communication from a foreign Patent Office in a counterpart foreign application, or to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of the statement.
- ☒ The Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment to Account No. 02-1440. *A duplicate copy of this sheet is enclosed for this purpose.*

Very respectfully,

Baxter Healthcare Corporation

Reg. No. 42,543

Austin J. Foley  
Baxter International Inc.  
One Baxter Parkway  
Deerfield, Illinois 60015  
Telephone: (847) 948-3315

When phoning re this application,  
please call (847) 948-2000

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, Arlington, VA on June 30, 2005.

Reg. No. 42,543

Austin J. Foley

INFORMATION DISCLOSURE STATEMENT BY  
APPLICANT


Use several sheets if necessary)  
Sheet 1 of 1

Applicant:  
Simpson et al.

Filing Date  
December 30, 2003

Examiner:  
Unknown

Group Art  
3763

[illegible][illegible][illegible]

Date Considered 05/20/2009

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).